Melinta Therapeutics

Company Listings from SPi: Melinta Therapeutics

You are here: Home >> SPi Company Listings >> Melinta Therapeutics

 

Melinta Therapeutics

Website:
http://

Search for other references to "melinta" on SPi News

Latest Melinta Therapeutics News

Melinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018 NEW HAVEN, Conn., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel anti...... 13:00 GMT Monday 24th September 2018

Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam)          NEW HAVEN, Conn., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializi...... 12:37 GMT Friday 21st September 2018

Melinta Therapeutics Names Peter Milligan as Chief Financial Officer NEW HAVEN, Conn., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antib...... 13:00 GMT Tuesday 18th September 2018

Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference NEW HAVEN, Conn., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antib...... 13:00 GMT Thursday 6th September 2018

Melinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference NEW HAVEN, Conn., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibio...... 13:00 GMT Wednesday 29th August 2018

Melinta Therapeutics Reports Second Quarter 2018 Financial Results NEW HAVEN, Conn., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibi...... 12:00 GMT Tuesday 7th August 2018

Melinta Therapeutics Announces Vabomere™ (meropenem and vaborbactam) Granted New Technology Add-On Payment by CMS NEW HAVEN, Conn., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antib...... 18:31 GMT Friday 3rd August 2018

Melinta Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018 NEW HAVEN, Conn., July 11, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibio...... 13:00 GMT Wednesday 11th July 2018

Melinta Therapeutics to Present at the JMP Securities Life Sciences Conference NEW HAVEN, Conn., June 13, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibio...... 21:05 GMT Wednesday 13th June 2018

Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20 Presentations at ASM Microbe 2018 NEW HAVEN, Conn., May 31, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibio...... 13:00 GMT Thursday 31st May 2018

Buy Melinta Therapeutics
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us